Life Matters

Life Matters is a preclinical-stage biopharmaceutical company focused on tackling antibiotic-resistant bacteria. The company has developed a new solution for fighting the resistant bacteria often acquired in hospitals by preventing the bacterias biofilm mode of growth, resulting in a more treatable infection. Morbidity and mortality in chronic lung infections are often tied to biofilm-related P. aeruginosa. Eliminating the bacterial biofilm enables the innate immune system to eradicate the infection. Life Matters small molecules do not possess any resistance-creating selective pressure, and its compounds are effective against a wide variety of gram negative and positive pathogens. The companys lead product is API, IBF-2, a compound with an innovative mechanism of action that can attenuate the biofilm mode of growth, a crucial phenotype that allows bacteria to survive environmental stresses such as antibacterial agents or the hosts immune system.

Life Matters was founded in 2016 by Amit Elbaz (Co-founder & CEO), Prof. Robert S. Marks (Co-founder & Scientific Advisor), Karina Golberg (Co-founder , Inventor & Chief Research Officer), Prof. Ariel Kushmaro (Co-founder, Inventor & Scientific Advisor).

Life Matters operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Healthcare, Providers.

Life Matters is based in Ein Karem, Jerusalem, Israel, Jerusalem District,South District.